"We are very fortunate to add Andreas to the leadership team of thecompany," said Ludo Reynders Ph.D., CEO of AAI Pharma. "His vast drugdevelopment experience and track record, especially in the ClinicalOncology area, will be invaluable in the further development of our globalclinical development business unit. As we organize our business around thecustomer, Andreas' scientific understanding and business acumen willprovide great value to the customers and project teams we serve."

Dr. Reynders continued: "The addition of Dr. Wolter to Andreas' teamaugments our strong foothold in Europe and his experience enhances ourability to perform large-scale global trials in key therapeutic areas."

Dr. Dreps brings to AAIPharma more than 15 years of drug developmentexperience including, most recently, leading the oncology therapeutic areafor ICON, a large, global CRO. His prior experience includes a series ofprogressively responsible positions with leading pharmaceutical companiesincluding, Merck KGaA, Rhone Poulenc Rorer/Aventis, and BristolMyers-Squibb. He received his undergraduate degree in Biology after studiesin Cologne, Bochum, and Munich, Germany and he obtained his Ph.D. followingresearch at the Max-Plank Institute and Stanford University. He completed apost-doctoral fellowship at Sugen Inc., in California.

Dr. Wolter possesses over 12 years of clinical research experience,including early clinical development, trial management, project management,training and business development. After 10 years at a leading, global CROwhere he managed large full-service trials, Dr. Wolter more recently servedas Vice President of Clinical Development for Apogenix, a German biotechcompany focused on oncology. Dr. Wolter received his M.Sc. and Ph.D. inbiology from Johann Wolfgang Goethe University in Frankfurt and completedpost-doctoral fellowships at both Goethe University and GutenbergUniversity. His extensive therapeutic experience includes, oncology,cardiovascular and infectious disease.

About AAIPharma

AAIPharma Inc. is a global drug development services company. We assist thepharmaceutical, biotechnology, and medical device industries in thepharmaceutical development, early clinical development and late-stageclinical development of their product portfolios. AAIPharma's serviceofferings include: analytical services, product development services, drugdelivery technologies, contract manufacturing (solids and parenterals),clinical services (Phase I-IV), clinical packaging and distribution andbioanalytical services.

For more information on the Company, please visit AAIPharma's website atwww.aaipharma.com.

Contact:Barry JohnsonEmail Contact